Zevra Therapeutics, Inc. (ZVRA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

SA Transcripts 162.21K Followers Follow Zevra Therapeutics, Inc. ( ZVRA ) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 5:35 PM EDT Company Participants Neil McFarlane - President, CEO & Director Justin Renz - CFO & Treasurer Presentation Unknown Analyst It's been a long day for you. Hopefully, we'll get through this efficiently, but also be able to have an opportunity to explain your story to the folks here today and those listening in. Question-and-Answer Session Unknown Analyst So maybe before we get started, Neil, your mission is to redefine what's possible for people with rare diseases. What does that mean to you and your team? Neil McFarlane President, CEO & Director Yes, first of all, thank you for having us. We've had a great day today. We really appreciate the support of Morgan Stanley. I will be making forward-looking statements, so I'd ask for everybody to take a look at our most recent SEC filings to ensure that you get the most up-to-date information. On behalf of Justin and the rest of the team, I really appreciate answering this question because what we do in the rare disease world is clearly a challenging part of pharmaceutical development and bringing medicines to people who otherwise have no other opportunity to get medicines. Now, rare disease is not as unique as it once was 20 or 30 years ago, but what we do hasn't changed much. We're trying to develop medicines and redefine how we get them to patients to then impact their lives. For us, we're doing that in a commercial sense today, primarily with commercial programs in Niemann-Pick disease type C, ultra-orphan, along with UCD. But in addition to that, we're also expanding globally to patients outside of the U.S. And we have a Phase 3 program also going in Vascular Ehlers-Danlos Syndrome. So for us, it's ultra-orphan diseases. We're talking about prevalence